Business2h ago
Dr. Reddy’s forays into India’s biosimilar immuno-oncology market, launches Nivorz
In 2025, the immuno-oncology market in India was estimated to be around ₹3,900 crore and predominantly driven by checkpoint inhibitors such as nivolumab, pembrolizumab and toripalimab.
This story was originally reported by The Hindu — Business. As an automated real-time news aggregator, NewsToolBar provides multi-perspective indexing and AI summarization while directing full readership directly to primary publisher sources.
ALSO REPORTED BY OTHER SOURCES (1)
Samson, Reddy lead India to series-clinching win over Afghanistan
Community Sentiment & Coverage Reliability
Crowd-sourced evaluation based on verified reader feedback
Rate Coverage Tone:
No reader evaluations recorded yet — be the first to rate the coverage tone above!
Quick Story Reactions:
Community Discussion (0)
Join the Community Discussion
Sign in or create a free reader account to post comments, upvote analysis, and share your perspective.